1
|
Bloemendal M, Bol KF, Boudewijns S, Gorris MA, de Wilt JH, Croockewit SA, van Rossum MM, de Goede AL, Petry K, Koornstra RH, Figdor C, Gerritsen WR, Schreibelt G, de Vries IJM. Immunological responses to adjuvant vaccination with combined CD1c + myeloid and plasmacytoid dendritic cells in stage III melanoma patients. Oncoimmunology 2021; 11:2015113. [PMID: 36524210 PMCID: PMC9746622 DOI: 10.1080/2162402x.2021.2015113] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
We evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally occurring dendritic cells (nDCs). Fifteen patients with completely resected stage III melanoma were randomized to receive adjuvant dendritic cell vaccination with CD1c+ myeloid dendritic cells (cDC2s), plasmacytoid dendritic cells (pDCs) or the combination. Immunological response was the primary endpoint and secondary endpoints included safety and survival. In 80% of the patients, antigen-specific CD8+ T cells were detected in skin test-derived T cells and in 55% of patients, antigen-specific CD8+ T cells were detectable in peripheral blood. Functional interferon-γ-producing T cells were found in the skin test of 64% of the patients. Production of nDC vaccines meeting release criteria was feasible for all patients. Vaccination only induced grade 1-2 adverse events, mainly consisting of fatigue. In conclusion, adjuvant dendritic cell vaccination with cDC2s and/or pDCs is feasible, safe and induced immunological responses in the majority of stage III melanoma patients.
Collapse
Affiliation(s)
- Martine Bloemendal
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, the Netherlands,Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Kalijn F. Bol
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, the Netherlands,Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Steve Boudewijns
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, the Netherlands,Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Mark A.J. Gorris
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, the Netherlands
| | | | | | | | - Anna L. de Goede
- Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Katja Petry
- Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
| | - Rutger H.T. Koornstra
- Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Carl Figdor
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, the Netherlands,Oncode Institute, Utrecht, the Netherlands
| | - Winald R. Gerritsen
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Gerty Schreibelt
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, the Netherlands
| | - I. Jolanda M. de Vries
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, the Netherlands,CONTACT I. Jolanda M. de Vries Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, the Netherlands
| |
Collapse
|
2
|
Bol KF, van den Bosch T, Schreibelt G, Mensink HW, Keunen JE, Kiliç E, Japing WJ, Geul KW, Westdorp H, Boudewijns S, Croockewit SA, van Rossum MM, de Goede AL, Naus NC, van der Graaf WT, Gerritsen WR, de Klein A, Punt CJ, Figdor CG, Cohen VM, Paridaens D, de Vries IJM. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology 2016; 123:2265-7. [DOI: 10.1016/j.ophtha.2016.06.027] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 06/04/2016] [Accepted: 06/06/2016] [Indexed: 10/21/2022] Open
|